Home > Urology > EAU 2019 > Bladder Cancer > Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer

Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer

Presented By
Prof. Jürgen Gschwend, Prof. Sergio Bracarda
Conference
EAU 2019
There was a very practical debate between Prof. Jürgen Gschwend (Technical University München, Germany) and Prof. Sergio Bracarda (Ospedale San Donato, Italy) about how to treat patients with limited pelvic lymph node involvement in otherwise localised bladder cancer. The discussion was multidisciplinary, and a consensus treatment pathway was agreed upon (see Figure). Figure: Consensus treatment pathway In cisplatin-eligible patients, induction chemotherapy is advocated. Subsequently, patients are then stratified according to their response, choosing additional surgery (radical cystectomy with extended pelvic lymph node dissection) or second-line systemic treatment. In cisplatin-ineligible patients, Prof. Bracarda urged that it is essential to enrol as many of these patients as possible in...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on